Trial Profile
Accompanying research of Phase II study for efficacy and safety of pembrolizumab for the cytotoxic chemotherapy unfit previously untreated patients highly expressing PD-L1 positive advanced non-small cell lung cancer (1888)
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 29 Mar 2019
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacodynamics
- Acronyms 1888-A
- 22 Mar 2019 Planned End Date changed from 31 Mar 2019 to 31 Mar 2022.
- 29 Mar 2017 New trial record